MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a “negative trend” opinion for the upcoming June CHMP vote

Subject to the formal CHMP vote expected in the June Meeting, the Company plans to request a re-examination procedure for the application

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, that it has been informed by the CHMP of the EMA of a “negative trend” opinion on its conditional Marketing Authorization Application (MAA) for MaaT013 (Xervyteg®) for the treatment of acute Graft-versus-Host Disease (aGvHD), following its recent CHMP oral explanation.